XML 52 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Description of Organization, Business Operations and Liquidity (Details Narrative)
 6 Months Ended 8 Months Ended 12 Months Ended
Jun. 28, 2023
USD ($)
$ / shares
shares
Jun. 20, 2023
$ / shares
shares
Jun. 07, 2023
shares
May 04, 2023
$ / shares
shares
Apr. 04, 2023
Feb. 03, 2023
USD ($)
$ / shares
shares
Jan. 30, 2023
shares
Nov. 08, 2021
USD ($)
$ / shares
shares
Nov. 05, 2021
shares
Jun. 30, 2023
USD ($)
Integer
$ / shares
shares
Jun. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
Integer
$ / shares
shares
Mar. 23, 2023
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Condition for future business combination number of businesses minimum | Integer                   1     1  
Number of shares issued | shares   750,000                        
Deferred underwriting fee payable                   $ 14,700,000   $ 14,700,000 $ 14,700,000  
Payments for investment of cash in trust account                       351,900,000  
Condition for future business combination use of proceeds percentage                   80.00%     80.00%  
Condition for future business combination threshold ownership (as a percent)                   50.00%     50.00%  
Maximum net tangible assets                   $ 5,000,001     $ 5,000,001  
Conversion ratio             1              
Cash withdrawn from Trust Account in connection with redemption                   333,270,649      
Cash and marketable securities held in Trust Account           $ 25,000,000       $ 25,675,938   351,915,805 $ 356,864,000  
Past fee due balance                           $ 151,000
Written notice description         On April 4, 2023, the Company received a written notice (the “April Notice”) from the Nasdaq indicating that the Company was not in compliance with Listing Rule 5450(b)(2)(A), requiring the Company to maintain a Market Value of Listed Securities (“MVLS”) of $50,000,000 for the continued listing of its securities on The Nasdaq Global Market. The April Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on Nasdaq. The April Notice states that the Company has 180 calendar days, or until October 2, 2023, to regain compliance with Listing Rule 5450(b)(2)(A). If at any time during this compliance period the Company’s MLVS closes at $50,000,000 or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with a written confirmation of compliance, and this matter will be closed.                  
Redemption limit percentage without prior consent                   15.00%     15.00%  
Obligation to redeem public shares if entity does not complete a business combination                   100.00%     100.00%  
Maximum allowed dissolution expenses                   $ 100,000     $ 100,000  
Cash held in operating bank accounts                   25,000,000     129,186  
Cash                   556,010   $ 344,581 129,186  
[custom:WorkingCapital-0]                   821,285        
Income on investments held in Trust Account                   $ 2,100,000     $ 4,948,000  
Months to complete acquisition                         15 months  
Redemption period upon closure                         10 days  
Working capital                         $ 76,098  
Tevogen Bio Securities [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Business combination, consideration transferred $ 1,200,000,000                          
Stock issued for acquisition | shares 20,000,000                          
Business combination, description (a) $15.00 per share for 20 out of any 30 consecutive trading days beginning on the Closing Date of the Merger Agreement until the 36-month anniversary of the Closing Date, in which case the holders of Tevogen Bio securities shall be entitled to receive an additional 6,666,667 shares of Common Stock, (b) $17.50 per share for 20 out of any 30 consecutive trading days beginning on the Closing Date of the Merger Agreement until the 36-month anniversary of the Closing Date, in which case the holders of Tevogen Bio securities shall be entitled to receive an additional 6,666,667 shares of Common Stock and (c) $20.00 per share for 20 out of any 30 consecutive trading days beginning on the Closing Date of the Merger Agreement until the 36-month anniversary of the Closing Date, in which case the holders of Tevogen Bio securities shall be entitled to receive an additional 6,666,666 shares of Common Stock. In addition, for each Earnout Share Payment, the Company will also issue to Sponsor an additional 1,500,000 shares of Company Common Stock.                          
Sponsor [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Number of shares issued | shares 1,500,000                          
Private Placement Warrants [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Number of warrants issued to purchase ordinary shares (in shares) | shares                   725,000     725,000  
Tevogeb Bio Holdings Inc [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Purchase price, per unit | $ / shares $ 11.50                          
Charter Amendment [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Minimum period to file charter amendment           15 days                
Cash withdrawn from Trust Account in connection with redemption           $ 332,000,000                
Common Class A [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Shares issued upon conversion | shares             11,983,333              
Common stock shares issued | shares             47,933,333     13,433,333   1,450,000 1,450,000  
Common stock shares outstanding | shares             47,933,333     13,433,333   1,450,000 1,450,000  
Common stock, par value | $ / shares 0.0001 $ 0.0001               $ 0.0001   $ 0.0001 $ 0.0001  
Exrecise price | $ / shares $ 11.50                          
Common Class B [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Shares cancelled | shares             11,983,333              
Common stock shares issued | shares             0     0   11,983,333 11,983,333  
Common stock shares outstanding | shares             0     0   11,983,333 11,983,333  
Common stock, par value | $ / shares                   $ 0.0001   $ 0.0001 $ 0.0001  
Public Shares [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Common stock shares outstanding | shares           2,383,053                
Public Shares [Member] | Charter Amendment [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Number of shares held by the shareholders exercised their right to redeem shares | shares           32,116,947                
Price per share | $ / shares           $ 10.34                
SSVK Associates, LLC [Member] | Purchase Agreement [Member] | Sponsor [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Number of shares issued | shares     7,988,889                      
SSVK Associates, LLC [Member] | Common Class A [Member] | Purchase Agreement [Member] | Sponsor [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Number of warrants issued to purchase ordinary shares (in shares) | shares     500,000                      
Number of shares issued | shares     1,000,000 7,988,889                    
Purchase price, per unit | $ / shares       $ 1.00                    
IPO [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Sale of units, net of underwriting discounts (in shares) | shares               30,000,000            
Proceeds from issuance initial public offering               $ 300,000,000            
Purchase price, per unit | $ / shares               $ 10.00   $ 10.20     $ 10.20  
Deferred underwriting fee payable               $ 14,700,000            
Offering costs               21,266,594            
Underwriting fees               6,000,000            
Other offering costs               566,594            
Payments for investment of cash in trust account               $ 351,900,000            
IPO [Member] | Private Placement Warrants [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Purchase price, per unit | $ / shares               $ 10.20            
Payments for investment of cash in trust account               $ 351,900,000            
IPO [Member] | Fee Reduction Agreement [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Number of shares issued | shares 500,000                          
Deferred underwriting fee payable $ 5,000,000                          
Deferred underwriting fee forfeited $ 9,700,000                          
Private Placement [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Number of warrants issued to purchase ordinary shares (in shares) | shares               1,360,000            
Price of warrant | $ / shares               $ 10.00            
Proceeds from sale of warrants               $ 13,600,000            
Private Placement [Member] | Private Placement Warrants [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Number of warrants issued to purchase ordinary shares (in shares) | shares               1,450,000            
Price of warrant | $ / shares               $ 10.00            
Proceeds from sale of warrants               $ 14,500,000            
Private Placement [Member] | Sponsor [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Sale of units, net of underwriting discounts (in shares) | shares               90,000            
Proceeds from issuance initial public offering               $ 900,000            
Private Placement [Member] | Sponsor [Member] | Private Placement Warrants [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Number of warrants issued to purchase ordinary shares (in shares) | shares               1,300,000            
Private Placement [Member] | SSVK Associates, LLC [Member] | Purchase Agreement [Member] | Sponsor [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Number of shares issued | shares       1,000,000                    
Over-Allotment Option [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Sale of units, net of underwriting discounts (in shares) | shares               4,500,000 4,500,000 4,500,000     4,500,000  
Proceeds from issuance initial public offering               $ 45,000,000            
Deferred underwriting fee payable               $ 2,700,000            
Common Stock [Member] | Common Class B [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Number of shares issued | shares                       11,983,333    
Common Stock [Member] | IPO [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Sale of units, net of underwriting discounts (in shares) | shares               30,000,000            
Purchase price, per unit | $ / shares               $ 10.00            
Proceeds from issuance initial public offering               $ 300,000,000